Lise Christensen

Lise Christensen

Auto-generated profile, based on publicly available information

Lise Christensen

Department of Pathology, Bispebjerg Hospital, University of Copenhagen, Copenhagen NV, DK-2400, Denmark

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
LCLise Christensen
Lise Christensen
VBVibeke Breiting
Vibeke Breiting
MJMartin Janssen
Martin Janssen
JVJens Vuust
Jens Vuust
Estrid HøgdallEstrid Høgdall
Estrid Høgdall

1 May 2003 in Plastic and Reconstructive Surgery
Verified
Journal Article
Closed access
LCLise H. Christensen
Lise H. Christensen
VBVibeke B. Breiting
Vibeke B. Breiting
AAAnnet Aasted
Annet Aasted
AJAnna Jørgensen
Anna Jørgensen
IKIvan Kebuladze
Ivan Kebuladze
Polyacrylamide hydrogel is an atoxic, stable, nonresorbable sterile watery gel consisting of approximately 2.5% cross-linked polyacrylamide and nonpyrogenic water. Polyacrylamide hydrogel is widely used in ophthalmic operations, drug treatment, food packaging products, and water purification. In the former Soviet Union, polyacrylamide hydrogel has been used in plastic and aesthetic surgery for more than 10 years, and Kiev City Hospital treats approximately 300 women a year for breast augmentation using the polyacrylamide hydrogel Interfall (Contura SA, Montreux, Switzerland). Capsule shrinkage following these injections has never been observed. The authors examined breast tissue samples from a total of 27 women who had polyacrylamide hydrogel injected at Kiev City Hospital up to 8 years and 10 months earlier. Age at operation, duration of polyacrylamide hydrogel implantation, history of possible side effects to the gel injection, other intercurrent diseases, the reason for present open breast operation, and breast palpation findings before operation were in each case compared with the histological findings on samples taken from breast tissue bordering the gel. The gel presented itself as a dark violet, homogenous mass with a rounded or ragged outline in large or medium-size deposits and as elongated strands, which mimicked the extracellular matrix, in small deposits. Histological findings of the breast tissue bordering the gel showed three different patterns: large collections of gel gave rise to a thick, soft-looking cellular membrane of macrophages and foreign-body giant cells; medium-size deposits were surrounded by just a thin layer of macrophages; and small deposits were not associated with any reaction in the surrounding tissue. Projections of the cellular soft membrane, known as granulomas, were seen in six patients. The granulomas were composed of macrophages, foreign-body giant cells, lymphocytes, and blood cells. A thin layer of fibrous connective tissue was occasionally present around the foreign-body membrane, but the thick fibrous capsule, which has been described in connection with silicone implants, was completely absent. The gel changes could be correlated to neither time since gel injection nor a history of recent injury or inflammation. It is concluded that the polyacrylamide hydrogel Interfall, which has been used in the former Soviet Union, is stable over time, nondegradable, confined to the breast, and diffusion and migration resistant. When the hydrogel is injected in medium-size or large quantities a cellular foreign-body reaction occurs, but in small amounts it is capable of splitting up individual connective tissue fibers and fat cells, substituting for the extracellular connective tissue matrix without eliciting any foreign-body reaction. As far as these data are concerned, polyacrylamide hydrogel is well tolerated by the breast and does not give rise to severe fibrosis, pain, or capsule shrinkage. However, to determine safety with more certainty, a larger sample size would be necessary.

1 September 2003 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
CHClaus Kim Høgdall
Claus Kim Høgdall
JJJulia Sidenius Johansen
Julia Sidenius Johansen
SKSusanne K. Kjaer
Susanne K. Kjaer
PPPaul A. Price
Paul A. Price
LCLise Christensen
Lise Christensen
CHClaus Kim Høgdall
Claus Kim Høgdall
YKL-40 (human cartilage glycoprotein-39) is a member of family 18 glycosyl hydrolases. YKL-40 is a growth factor and is secreted by cancer cells. High serum levels of YKL-40 in patients with colorectal cancer and recurrent metastatic breast cancer have been associated with a poor prognosis. We evaluated the prognostic value of plasma YKL-40 in patients with primary ovarian cancer (OC). YKL-40 was determined by ELISA in plasma obtained preoperatively from 47 women with stage III OC and in plasma from 79 healthy females. The results showed that plasma YKL-40 was elevated compared to healthy females in 57% of the OC patients and was highest in the patients who died during the follow-up compared to the patients still alive (186 vs. 78 µg/l, p=0.002). Patients with high plasma YKL-40 (>130 µg/l) had significantly (p=0.0003) shorter survival than patients with normal plasma YKL-40. Multivariate Cox regression analysis showed that plasma YKL-40 (RH=3.95; 95% CI, 1.52-10.27; p=0.005) and radicality after primary surgery (RH=4.03; 95% CI, 1.81-8.97; p=0.001) were independent prognostic factors of survival, whereas age, histological type of tumour and serum CA125 had no independent prognostic value. In conclusion, plasma levels of YKL-40 proved of prognostic value in stage III OC patients.

15 November 2005 in European Journal of Plastic Surgery
Verified
Journal Article
Closed access
PDF file
LCLise Christensen
Lise Christensen
VBVibeke Breiting
Vibeke Breiting
JVJens Vuust
Jens Vuust
EHEstrid Hogdall
Estrid Hogdall

28 July 2004
Verified
Journal Article
Closed access
FBFarah Diba Begum
Farah Diba Begum
CHClaus Kim Høgdall
Claus Kim Høgdall
SKSusanne K. Kjaer
Susanne K. Kjaer
LCLise Christensen
Lise Christensen
JBJan Blaakaer
Jan Blaakaer
Estrid HøgdallEstrid Høgdall
Estrid Høgdall